Cardiomyopathy is diagnosed through a combination of physical examination, imaging tests, electrical recordings of the heart, blood work, and sometimes genetic testing or tissue biopsy. No single test confirms every type. Instead, doctors layer results from multiple tools to identify which form of cardiomyopathy is present, how severe it is, and what might be causing it.
Physical Exam and Medical History
The diagnostic process starts with a clinical evaluation that covers symptoms like shortness of breath during activity, fatigue, swelling in the legs or ankles, and any episodes of fainting or racing heartbeats. Your doctor will listen for heart murmurs, check whether the heartbeat feels displaced from its normal position on the chest wall, look for swelling, listen for crackling sounds in the lungs (a sign of fluid buildup), and examine the veins in your neck for unusual distension. A combination of six physical exam findings and three items from your history, including age and any prior coronary artery disease, has strong diagnostic accuracy for identifying heart failure related to cardiomyopathy.
Family history matters more here than in many other heart conditions. Most hereditary cardiomyopathies follow an autosomal dominant inheritance pattern, meaning first-degree relatives of someone with the condition have a 50% chance of carrying the same genetic variant. Your doctor will ask whether any close relatives have had unexplained heart failure, sudden cardiac death at a young age, or a known cardiomyopathy diagnosis.
Blood Tests and Biomarkers
A blood test measuring BNP or NT-proBNP helps determine whether the heart is under strain. These proteins are released when heart muscle is stretched beyond normal. Normal NT-proBNP levels fall below 125 pg/mL for people under 75 and below 450 pg/mL for those over 75. Levels above 900 pg/mL suggest heart failure. These numbers don’t pinpoint the type of cardiomyopathy, but they help confirm that something is wrong with heart function and guide the urgency of further testing. Troponin levels, which indicate heart muscle damage, may also be checked.
Electrocardiogram Patterns
An electrocardiogram (ECG) records the heart’s electrical activity and often shows abnormalities before imaging reveals structural changes. Different cardiomyopathies leave distinct electrical signatures.
In hypertrophic cardiomyopathy, abnormal Q waves appear in 18 to 53% of patients and can actually precede detectable thickening of the heart muscle by several years. Deep, symmetrically inverted T waves in the side leads of the heart are common, and when these inversions appear across all the front-facing leads, they suggest thickening concentrated at the heart’s apex.
Dilated cardiomyopathy produces Q waves in 10 to 25% of cases, reflecting the enlarged chamber and scarring within the muscle. Cardiac amyloidosis, a type of restrictive cardiomyopathy, has a particularly telling pattern: Q waves alongside unusually low voltage signals. This mismatch between low electrical voltage and a visibly thickened heart wall on imaging is a strong clue that amyloid protein is infiltrating the muscle. Arrhythmogenic cardiomyopathy shows inverted T waves in the right-sided leads, which is considered a major diagnostic criterion when other causes are ruled out.
Echocardiogram: The Core Imaging Test
An echocardiogram, an ultrasound of the heart, is the most important single test in cardiomyopathy diagnosis. It measures the size of the heart chambers, the thickness of the walls, and how effectively the heart pumps. The key measurement is ejection fraction (EF), the percentage of blood the left ventricle pushes out with each beat.
Each type of cardiomyopathy has a distinct echocardiographic profile:
- Dilated cardiomyopathy shows an enlarged left ventricle with a rounded shape, thinned walls, and an ejection fraction below 40%.
- Hypertrophic cardiomyopathy is diagnosed when any segment of the left ventricular wall measures 15 mm or thicker. The ejection fraction is usually normal or even elevated above 65%.
- Restrictive cardiomyopathy presents with normal or near-normal wall thickness and a preserved ejection fraction, at least until late in the disease. What distinguishes it is abnormal filling patterns: the stiff muscle resists relaxation, and Doppler measurements reveal that blood enters the ventricle in an abnormal, restricted way.
One diagnostically tricky situation involves athletes. Intense endurance training, particularly in sports like rowing and cycling, can thicken the heart wall into a “grey zone” of 13 to 15 mm, which overlaps with mild hypertrophic cardiomyopathy. About 2% of highly trained male athletes fall into this range. Several features help distinguish the two. Athletes typically have enlarged cavity dimensions above 55 mm, while hypertrophic cardiomyopathy patients usually have cavities smaller than 45 mm. Athletes also show normal filling patterns on Doppler studies, whereas most hypertrophic cardiomyopathy patients have abnormal filling regardless of symptoms. If the distinction remains unclear, a three-month break from training can resolve it: an athlete’s wall thickness will decrease by 2 to 5 mm, while hypertrophic cardiomyopathy will not regress. Notably, elite female athletes almost never develop wall thickness above 11 mm, so a woman presenting with thickness of 13 mm or more likely has true cardiomyopathy.
Cardiac MRI for Tissue Detail
Cardiac MRI provides a more detailed look at the heart muscle itself, particularly through a technique called late gadolinium enhancement (LGE). After a contrast agent is injected, areas of scarring or abnormal tissue light up on the scan. The location and pattern of this enhancement help identify both the type and severity of cardiomyopathy.
In hypertrophic cardiomyopathy, scarring typically appears in the middle layer of the thickened segments. In dilated cardiomyopathy, about 75% of patients show no scarring at all on MRI. When it does appear, in roughly 20 to 25% of cases, it follows a non-ischemic pattern in the middle of the wall or along the outer surface rather than the pattern seen after a heart attack. Midwall scarring in the septum, especially when it extends to the side wall in a ring-like pattern, signals a higher risk of dangerous heart rhythms.
Cardiac amyloidosis produces a highly specific pattern: diffuse enhancement along the inner lining of the heart that doesn’t follow the territory of any single coronary artery. As the disease advances, this enhancement becomes transmural, extending through the full thickness of the wall. This distinctive appearance on MRI can strongly suggest amyloidosis even before a biopsy is performed.
Genetic Testing
Genetic testing plays an increasingly central role, particularly in hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. Panels typically screen a set of genes known to cause cardiomyopathy, including MYH7, MYBPC3, TTN, LMNA, and several others linked to the structural proteins of heart muscle cells. The 2024 AHA/ACC guidelines for hypertrophic cardiomyopathy have reinforced the role of genetic evaluation in guiding management.
When a disease-causing variant is found in one family member, cascade screening becomes possible. This means other relatives can take a targeted genetic test for that specific variant. Those who test positive undergo regular cardiac screening with echocardiograms and ECGs, even if they have no symptoms yet. Those who test negative can be reassured and generally spared years of repeat monitoring. For conditions where the wall thickness or electrical changes develop gradually over time, this approach can catch problems years before they become dangerous.
Cardiac Catheterization
Cardiac catheterization measures pressures inside the heart chambers directly. It is not needed for most cardiomyopathy diagnoses but becomes important when restrictive cardiomyopathy needs to be distinguished from constrictive pericarditis, a condition where a stiff sac around the heart mimics the same symptoms. Both conditions produce exaggerated pressure swings during filling, but the specific patterns differ in ways that can only be captured by threading a pressure-sensing catheter into the right side of the heart.
Heart Biopsy
Endomyocardial biopsy, where a small sample of heart tissue is collected through a catheter, is reserved for cases where non-invasive testing cannot reach a clear diagnosis. The most common reasons include suspected cardiac amyloidosis, sarcoidosis, inflammatory cardiomyopathies, and storage diseases like hemochromatosis. For amyloidosis specifically, the tissue sample is stained and examined under polarized light. If misfolded amyloid protein is present, it produces a characteristic apple-green glow that is essentially diagnostic. Biopsy also helps identify whether heart failure has resulted from certain cancer treatments, another scenario where knowing the exact cause changes the treatment plan.